Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Net Cash Flow (2017 - 2025)

VYNE Therapeutics' Net Cash Flow history spans 9 years, with the latest figure at -$6.1 million for Q2 2025.

  • For Q2 2025, Net Cash Flow fell 158.12% year-over-year to -$6.1 million; the TTM value through Dec 2025 reached $5.8 million, up 153.54%, while the annual FY2025 figure was $4.1 million, 138.16% up from the prior year.
  • Net Cash Flow reached -$6.1 million in Q2 2025 per VYNE's latest filing, down from $8.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $61.0 million in Q1 2021 to a low of -$51.1 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$2.0 million, with a median of -$5.7 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 429.68% in 2023, then plummeted 1562.59% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$10.1 million in 2021, then soared by 54.24% to -$4.6 million in 2022, then surged by 429.68% to $15.2 million in 2023, then crashed by 76.05% to $3.6 million in 2024, then tumbled by 268.49% to -$6.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Net Cash Flow are -$6.1 million (Q2 2025), $8.2 million (Q1 2025), and $3.6 million (Q4 2024).